Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines

Circulation Journal

Volumn 67, Issue 1, 2003, Pages 46-48

  Kamijo, Yoshito ^a   Soma, Kazui ^a   Nagai, Tomonori ^a   Kurihara, Katsuyoshi ^a   Ohwada, Takashi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiphospholipid antibodies; Chlorpromazine; Pulmonary thromboembolism; Risperidone

Indexed keywords

BENZODIAZEPINE; BROMPERIDOL; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; HEPARIN DERIVATIVE; LEVOMEPROMAZINE; PERICIAZINE; PHENOTHIAZINE; PHOSPHOLIPID ANTIBODY; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SULTOPRIDE; UROKINASE;

ADULT; AGE; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; HUMAN; JAPAN; LUNG EMBOLISM; MALE; MEDICAL RECORD; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; RISK; TREATMENT OUTCOME;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PHENOTHIAZINES; PULMONARY EMBOLISM; RISPERIDONE; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; THROMBOEMBOLISM;

EID: 0037245162     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.67.46     Document Type: Article

References (15)

1. Tayama E, Ouchida M, Teshima H, Takaseya T, Hiratsuka R, Akasu K, et al. Treatment of acute massive/submassive pulmonary embolism. Circ J 2002;66:479-483.
2. Kumasaka N, Sakuma M, Shirato K. Incidence of pulmonary thromboembolism in Japan. Jpn Circ J 1999;63:825-827.
3. Nakamura M, Okada O, Sakuma M, Nakanishi N, Miyahara Y, Yamada N, et al. Incidence and clinical characteristics of chronic pulmonary thromboembolism in Japan compared with acute pulmonary thromboembolism: Results of a multicenter registry of the Japanese Society of Pulmonary Embolism Research. Circ J 2002; 66:257-260.
4. Hasegawa H. Current status of pulmonary thromboembolism: Incidence, diagnosis, classification, pathogenesis, and treatment. Jpn Circ J 1984;48:100-110.
5. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001;179:63- 66.
6. Ungvari G. Neuroleptic-related sudden death (proven or a mere hypothesis?). Pharmacopsychiatry 1980;13:29-33.
7. Hafner H, Brehm I. Thromboembolic complications in neuroleptic treatment. Compr Psychiatry 1965;6:25-34.
8. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997;8:671- 677.
9. Lacika S, Cooper JP. Pulmonary embolus possibly associated with clozapine treatment. Can J Psychiatry 1999;44:396-397.
10. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000;335:1155-1156.
11. Davis S, Kern HB, Asokan R. Antiphospholipid antibodies associated with clozapine treatment. Am J Hematol 1994;46:166-167.
12. Canoso RT, Oliveira RM, Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: Absence of thrombosis. Am J Hematol 1988;27:272-275.
13. Boullin DJ, Woods HF, Grimes RPJ, Grahame-Smith DG, Wiles D, Gelder MG, et al. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol 1975;2:29-35.
14. Orr MW, Boullin DJ. The relationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine. Br J Clin Pharmacol 1976;3:925-928.
15. Love RC. Novel versus conventional antipsychotic drugs. Pharmacotherapy 1996;16:6S-1OS.